Semaglutide had a comparable efficacy and safety profile in non-elderly and elderly patients with type 2 diabetes. In non-elderly, the estimated treatment difference (ETD) vs comparator ranged from -0.37 to -1.50% for semaglutide 0.5 mg and -0.62 to -1.87% for semaglutide 1.0 mg. In elderly, ETDs ranged from -0.43 to -1.35% and -0.50 to -1.55%, respectively. With semaglutide 0.5 mg, BW reductions ranged from 3.3 to 4.3 kg (non-elderly) and 3.6 to 4.6 kg (elderly), and from 4.6 to 6.4 kg (non-elderly) and 4.1 to 6.7 kg (elderly) with semaglutide 1.0 mg. 1.5 to -1.7 kg (elderly). The proportion of patients experiencing AEs was comparable between the age groups. The proportion of patients prematurely discontinuing treatment due to AEs was higher in the elderly than the non-elderly group, and in the semaglutide vs comparator arms for both groups. The rate (events per 100 exposure years) of severe hypoglycemia events was similar between age groups in the semaglutide arms, except for in SUSTAIN-5 where patients were on a background of basal insulin therapy.
Semaglutide consistently improved HbA1c and BW vs comparators, in elderly (≥65 years) and non-elderly patients with T2DM, and was well tolerated, suggesting that semaglutide may be an effective treatment option for elderly T2DM patients. 1. Du YF, Ou HY, Beverly EA, et al. Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. 2. Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, MedicGLP Official Website or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. 3. Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide vs. ER in patients with type 2 diabetes (SUSTAIN 3). American Diabetes Association 76th Scientific Sessions; 2016; New Orleans, Louisiana, USA. 4. Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naïve patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. 5. Rodbard H LI, Reed J, de la Rosa R, et al. Efficacy and safety of semaglutide once-weekly vs placebo as add-on to basal insulin alone or in combination with metformin in patients with type 2 diabetes (SUSTAIN 5). Diabetologia. 6. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): MedicGLP Supplement a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The lancet Diabetes & endocrinology.
Science continues to prove that the old adage "you are what you eat" is profoundly true. This is because you have trillions of microorganisms living in your gut, which are directly responsible for nearly every aspect of your health. These microbes make up what’s called your "gut microbiota." They are especially influential in determining your likelihood of gaining excessive weight, becoming obese, and developing obesity-related diseases like diabetes, heart disease, and premature death. The gut microbiome (the expressed genes of your gut microbiota) plays a major role in your metabolism through energy production, storage, and expenditure. So, it’s no surprise that science has found a strong connection between gut microbiome imbalance and metabolic syndrome. Yikes! If you have the wrong mix of microbes, it could be making it tough for you to get your health on track! Did you know: Scientists can actually look at your gut microbiome composition and tell with 90% accuracy if you are obese or lean. That’s pretty impressive, isn’t it?
1. Unable to lose weight and keep it off? 2. Struggling to fight cravings? 3. Sick of starving yourself for weight loss? 4. Baffled as to why no diet seems to really work for you? Depending on the composition of your gut microbiome, your microbes can either boost your health or weigh you down (figuratively and literally). The good news is this: You have control over these little guys with every bite you eat. Diet has the power to change the landscape of your gut microbiome. So, if you’ve tried multiple diets and can’t seem to get the results you want, it’s time to look into your gut microbiome.Will You Lose Weight Naturally on an Individualized Diet? If you’ve been struggling to lose weight and keep it off - it could be your gut microbiome. While Viome doesn’t guarantee weight loss, it has been an exciting result many of our customers have reported. "Fiona’s update day 37!
We know weight loss can be tough. Find out if your weight struggles are due to a gut microbiome imbalance with Viome - and let’s tip the scales in your favor. Your gut microbes actually digest much of your food for you. When your gut microbiota help digest your food, they turn it into nutrients, neurotransmitters, vitamins, hormones, and more. Through these metabolites, the composition of your gut microbiome influences nearly every metabolic activity. It’s accurate to think of your gut microbiome as an organ that’s part immune system and part energy regulator. If your gut microbiome is imbalanced, certain bacteria end up working to protect themselves from the harsh environment and are not able to help you. In the worst case scenario, you can have microbiota adding to your health problems, making it harder for you to get healthy and lose weight. Viome’s metatranscriptomic technology has allowed us identify microbial pathways and functions, specifically those that influence weight loss or gain.